ResMed (RMD) reported $1.29 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7.9%. EPS of $2.37 for the same period compares to $2.13 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.28 billion, representing a surprise of +0.53%. The company delivered an EPS surprise of +0.42%, with the consensus EPS estimate being $2.36.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• U.S., Canada, and Latin America- Devices: $422.70 million compared to the $426.47 million average estimate based on four analysts. The reported number represents a change of +5.9% year over year.
• U.S., Canada, and Latin America- Masks and other: $326.70 million versus $318.76 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.4% change.
• Combined Europe, Asia, and other markets- Total: $381.30 million versus $377.86 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
• Combined Europe, Asia, and other markets- Devices: $253.50 million versus $249.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
• Combined Europe, Asia, and other markets- Masks and other: $127.70 million versus the four-analyst average estimate of $128.11 million. The reported number represents a year-over-year change of +4.2%.
• U.S., Canada, and Latin America- Total: $749.30 million versus $745.22 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9% change.
• Global revenue- Total Sleep and Breathing Health: $1.13 billion compared to the $1.12 billion average estimate based on five analysts. The reported number represents a change of +7.8% year over year.
• Global revenue- Residential Care Software: $161.20 million versus the five-analyst average estimate of $161.15 million. The reported number represents a year-over-year change of +8.9%.
• Global revenue- Total Devices: $676.20 million compared to the $676.22 million average estimate based on four analysts. The reported number represents a change of +6% year over year.
• Global revenue- Total Masks and other: $454.40 million versus the four-analyst average estimate of $446.86 million. The reported number represents a year-over-year change of +10.6%.

View all Key Company Metrics for ResMed here>>>

Shares of ResMed have returned -3.3% over the past month versus the Zacks S&P 500 composite's -6.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ResMed Inc. (RMD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research